BioTime Signs Stem Cell Co-marketing Agreement With Millipore

Published: 09-Jul-2009

To make cell lines widely available to scientists worldwide, allowing them to more quickly perform the R&D work that may lead to life-saving therapies

Millipore and BioTime’s subsidiary, Embryome Sciences have entered into a co-marketing agreement. Under the agreement, Millipore would become a worldwide distributor of ACTCellerate human progenitor cell lines.

Donald O’Neil, Director of marketing for stem cells and cell biology at Millipore, said: “We believe that Embryome Sciences’ novel, highly-purified, and scalable progenitor lines have potential to be a significant breakthrough for the industry, and we’re excited to feature them in our rapidly growing family of novel stem cell lines, media, antibodies, cultureware, and characterization kits.

Michael West, CEO of BioTime and Embryome Sciences, said: “The ACTCellerate product line gives scientists a jump-start on their research by providing a reliable, highly purified source of characterized human progenitor cells from a variety of lineages. We look forward to working with Millipore’s outstanding marketing team to make these cell lines widely available to scientists worldwide, allowing them to more quickly perform the research and development work that may lead to life-saving therapies.”

Tell your friend about this article